Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Lion's Mane (Hericium erinaceus) | NSI-189 | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 500-3000 mg/day of fruiting body extract (standardized to >30% polysaccharides) or 1000-3000 mg/day of mycelium extract (erinacine-enriched) | 40 mg once daily (for educational context — investigational compound, not approved for any indication) |
| Timing | Morning or split morning/afternoon. With or without food. Effects are cumulative — expect 2-4 weeks before noticeable cognitive benefit. | Once daily, time of day not definitively established from clinical data. With or without food. |
| Cycle Duration | Ongoing; no cycling strictly required, though some users cycle 8 weeks on, 2 weeks off | Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable. |
| Evidence Level | moderate_human | moderate_human |
Contains hericenones (fruiting body) and erinacines (mycelium) that stimulate nerve growth factor (NGF) synthesis in glial cells via activation of the JNK pathway. Erinacines cross the blood-brain barrier via passive diffusion and act as potent neurotrophin-stimulating compounds, activating the TrkA receptor and downstream ERK1/2 signaling cascades to promote hippocampal neurogenesis and synaptic plasticity. Also demonstrates anti-inflammatory activity through suppression of NF-kB and upregulation of BDNF expression.
500-3000 mg/day of fruiting body extract (standardized to >30% polysaccharides) or 1000-3000 mg/day of mycelium extract (erinacine-enriched)
Morning or split morning/afternoon. With or without food. Effects are cumulative — expect 2-4 weeks before noticeable cognitive benefit.
Ongoing; no cycling strictly required, though some users cycle 8 weeks on, 2 weeks off
Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.
40 mg once daily (for educational context — investigational compound, not approved for any indication)
Once daily, time of day not definitively established from clinical data. With or without food.
Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →